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There is growing evidence to the importance of translational science and medicine in the improvement of patient
outcome, even though the definitions of translational science, translational medicine, and clinical and translational
medicine need to be further clarified. In the present perspective, we collected commentaries and descriptions
about clinical and translational medicine from some members of Clinical and Translational Medicine editorial board
to stimulate the discussion and help the understanding better.There is growing evidence to the importance of transla-
tional science and medicine in the improvement of
patient outcome, even though the definitions of transla-
tional science, translational medicine, and clinical and
translational medicine need to be further clarified.
Clinical and translational medicine is expected to in-
clude scientific and regulatory investigations to translate
preclinical researches to clinical application with a
specific emphasis on new biotechnologies, biomaterials,
bioengineering, disease-specific biomarkers, cellular and
molecular medicine, omics science, bioinformatics,
applied immunology, molecular imaging, drug discovery
and development, and regulation and health policy. It is
believed that clinical and translational medicine will
benefit and improve novel diagnostics/prognostics and
therapeutics for clinical use, post-genomic knowledge
and experience, and/or new disciplines that reflect
additional levels of complexity. We should clarify the
bioethics at the interface and paradigms between
technology and society, academies and industries, as well
as publics and private models. Translational medicine
should meet the demands of maintaining or expanding
the biomedical workforce and education programs that
attract and retain young people in the translational andCorrespondence: xiangdong.wang@clintransmed.org
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lected commentaries and descriptions about clinical and
translational medicine from some members of Clinical
and Translational Medicine editorial board to stimulate
the discussion and help the understanding better.
Barry S. Coller (David Rockefeller Professor of
Medicine; Head, Allen and Frances Adler Laboratory of
Blood and Vascular Biology; Physician-in Chief of the
Rockefeller University Hospital; and Vice President for
Medical Affairs, Rockefeller University) defines transla-
tional science as, “The application of the scientific
method to address a health need.” In contrast to basic
investigation, which has the generation of new know-
ledge as its primary goal, the primary of goal of transla-
tional science is improvement in human health.
John Hutton (Professor of Pediatrics, Vice President
and Director, Biomedical Informatics, Cincinnati Chil-
dren's Hospital Medical Center, University of Cincinnati)
describes that a perfectly reasonable, “official” definition
of translational research should be “Translational
research transforms scientific discoveries arising from
laboratory, clinical or population studies into new
clinical tools and applications that improve human
health by reducing disease incidence, morbidity and
mortality” modified from “Transforming Translation –
Harnessing Discovery for Patient and Public Benefit”
(Report of the Translational Research Working Group of
the National Cancer Advisory Board, US NIH, 2007).n Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Protein Science & Imaging, Dept. of Measurement,
Technology and Industrial Electrical Engineering, Lund
University, Sweden, and Professor, 1st Department of
Surgery, Tokyo Medical University, Japan. He was the
lead principle scientist of the AstraZeneca Global
Proteomics Network and developed clinical biomarker
platforms for clinical studies. He also serves as the presi-
dent of Swedish Proteomics Society and vice-president
of European Proteomics Association. Dr Marko-Varga
emphasizes that the modern health care is currently and
globally undergoing a big revolution, where innovative
therapies and novel technology advancements are having
profound impacts on improving patient care and man-
aging costs. Certainly, the latest frontiers in micro and
nano-technology which allows high resolution protein
sequence separation as well as Mass Spectrometry
imaging that can resolve drug deposition that are loca-
lized in tumor environments.
One cornerstone within Health Care that has had great
impact on cancer patients is the increasing number of
personalized medicines being introduced into the
market. The interest in personalized medicines actually
results from understanding the molecular biology of
diseases. This is mandatory, where the alignment of
molecular signatures with particular disease forms, and
our ability to measure markers associated with prognosis
and outcomes is at the focus of Clinical and Transla-
tional Medicine. In this respect, personalized medicines
treatment has now become a part of large cohort stud-
ies. I have been involved in large such non-small cell
lung cancer (NSCLC) in several studies in Asia, and the
outcome and impact has been overwhelming. In my
view, the Clinical and Translational Medicine is a re-
search field that bridges knowledge of disease processes,
gained by in vitro and experimental animal models, with
the disease pathways found in humans.
It is my vision that we expect from the research field of
Clinical and Translational Medicine that a final goal is
to develop helps the suffering patients with new diag-
nostics, drug products, and new medical knowledge for
treating disease throughout the phases of clinical devel-
opment. As an example, the Japanese authorities are
working on a concept that will require for new drugs
introduced to the market, that a diagnostic test is avail-
able improve on drug efficacy. The Biomarker assay is
associated to the drug, and the patient stratification. We
are expecting that such drug products will prove to be
more efficacious within the targeted disease process, but
also free from unwanted side effects and toxicity.
William Rhodes (Senior Vice President, Corporation
Strategy and Development of BD, from a Life Sciences
Professional’s View on CTM) defines that remarkable
advances in technologies and the resulting methods usedto explore and unlock the biology of cells are now being
employed to discover, elucidate and create well-defined
and strategically selected treatment modalities for
numerous diseases. These same tools may then use to
diagnose and classify the disease, select patients for
whom the therapy is best suited, and then employed to
monitor treatment effectiveness.
A confluence of technologies and capabilities has
occurred making this possible – powerful methods for
probing cells, such as mass spectrometry, flow cytome-
try, gene sequencing, image analysis, various detection
modalities for measuring cause and effect within, on and
between cells – all are directed towards not only under-
standing the cells in question, but also the diseases they
cause, or in some cases, combat.
With the advent of such powerful tools has come a
deluge of data – which now, because of significant
advances in computational capability, information
technology, data text mining and the like, can be effect-
ively reviewed, analyzed and discoveries made.
Clinical translational medicine has emerged – based on
the synthesis of information gleaned from multiple in-
vestigative sources, human biology and diseases are bet-
ter understood and therapies more rapidly identified and
tested, which, taken together, result in improved patient
treatment and outcomes.
Dr Dongming Hou (Senior Scientist in Saint Joseph’s
Hospital Atlanta/Saint Joseph’s Translational Research
Institute, and Clinical Research Associate Professor at
Department of Pharmacy Practice of Mercer University)
thinks that translating scientific discoveries from a
potential new medical device, drug, method, molecule
into modern therapies also need a multidisciplinary
team, which include scientist, physician, biomedical
engineers, quality control, regulatory, business etc. Safety
may be more important requirement for preclinical than
efficacy especially in device field. Since human is much
more complex than animal, the efficacy in preclinical
model sometimes is not translate equally.
Stephen I. Hsu (one of global leading scientists in transla-
tional medicine) emphasized that the topic of a "social mis-
sion" should be also important for clinical translational
scientists, to think ahead about how to translate in a man-
ner that will enable public health models for disease pre-
vention or treatment in low-resource settings to be
realistically and successfully implemented. High technology
approaches can either produce expensive therapies with
relatively small impact if the target population is small
(gene therapy or stem cell & regenerative medicine for rare
diseases, etc.), or it can produce affordable low-tech and
self-administered therapies that are targeted towards
addressing common diseases (e.g. pandemics such as
obesity and its related complications such as type 2 dia-
betes, highly prevalent cancers prevented by novel low-cost
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be effective and available to both the most wealthy and the
most impoverished. Medical advancement should be
informed by the need to achieve global health equity. A
social mission is part of our mandate as “translationists”.
And often it starts by conceptualizing the public health
care model that is most likely to work, identifying the chal-
lenges that must be overcome and then developing and
bringing to market novel diagnostics, prognostics and ther-
apeutics that meet urgent and unmet global needs.
Claudio Spada (Consultant of Information Systems and
Communication Technology, Anaesthesia and Intensive
Care Department, Fatebenefratelli & Ophthalmiatric Hos-
pital, Milan, Italy), suggested Clinical and Translational
Medicine as “The art to use scientific concepts and proce-
dures to create interactions and synergies between differ-
ent scientific medical disciplines and clinical practices,
with a multi-modal process that integrates the exchange of
information in order to optimize the efficiency and efficacy
of the research, and advance the knowledge that can im-
prove the patient care with better clinical applications”.
Given the present scenario of the scientific publishing
market and the specificity of the publication, the journal of
CTM should also be seen as hub or platform for training
programs in translational research, considering also the
potentiality and opportunity of the on-line systems and
technology. CTM should also propose and promote initia-
tives that use the new-generation interactive educational
tools, like open Internet platform, to fulfill the unmet
need of disseminating new knowledge in clinical and
translational medicine that can lead to a better clinical
practice. Some references related to these ideas include
Patay BA, Topol EJ. The unmet need of education in
genomic medicine. Am J Med. 2012 Jan; 125(1):5–6;
Rubio DM, Schoenbaum EE, Lee LS, Schteingart DE,
Marantz PR, Anderson KE, Platt LD, Baez A, Esposito
K. Defining translational research: implications for
training. Acad Med. 2010 Mar;85(3):470–5; Woo KT,
Wong KS, Lee EJ, Chan CM. How can we Improve
Clinical Research in Clinical Practice with Better Re-
search Outcome? Ann Acad Med Singapore. 2011
Nov;40(11):499–8.
In conclusion, it is important and critical to under-
stand the definition and concept of clinical and transla-
tional medicine and allow the variations of the
understanding. The present Commentary is expected to
initiate and stimulate the discussion of understanding
about clinical and translational medicine.
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